Sex Hormones and Immune Regulation in Ovarian Cancer

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 31

PMID 39738765

Authors

Rui Zhao

Wenqin Lian

Qiong Xu

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer continues to be a major cause of morbidity and mortality in women, with immune regulation playing a critical role in its progression and treatment response. This review explores the interplay between sex hormones, particularly estrogen and progesterone, and immune regulation in ovarian cancer. We delve into the mechanisms by which these hormones influence immune cell function, modulate immune checkpoints, and alter the tumor microenvironment. Key pathways involving estrogen and progesterone receptors are examined, highlighting their impact on tumor growth and immune evasion. The review also discusses the therapeutic implications of these interactions, including the potential for combining hormone-based therapies with immune checkpoint inhibitors. Personalized medicine approaches, leveraging biomarkers for predicting treatment response, are considered essential for optimizing patient outcomes. Finally, we address current research gaps and future directions, emphasizing the need for advanced research technologies and novel therapeutic strategies to improve the treatment of ovarian cancer through a better understanding of hormone-immune interactions.

References

Gupta M, Srikrishna G, Klein S, Bishai W . Genetic and hormonal mechanisms underlying sex-specific immune responses in tuberculosis. Trends Immunol. 2022; 43(8):640-656. PMC: 9344469. DOI: 10.1016/j.it.2022.06.004. View

Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

Pawlowska A, Kwiatkowska A, Suszczyk D, Chudzik A, Tarkowski R, Barczynski B . Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients. Int J Mol Sci. 2021; 22(21). PMC: 8583913. DOI: 10.3390/ijms222111563. View

Liu T, Huang Y, Lin H . Estrogen disorders: Interpreting the abnormal regulation of aromatase in granulosa cells (Review). Int J Mol Med. 2021; 47(5). PMC: 7952251. DOI: 10.3892/ijmm.2021.4906. View

Fournier A, Cairat M, Severi G, Gunter M, Rinaldi S, Dossus L . Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study. J Natl Cancer Inst. 2023; 115(6):671-679. PMC: 10248854. DOI: 10.1093/jnci/djad035. View

Colombo N, Sessa C, Bois A, Ledermann J, McCluggage W, McNeish I . ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019; 30(5):672-705. DOI: 10.1093/annonc/mdz062. View

Wu C, Pan K, Chen J, Tao Y, Liu Y, Chen B . Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment. Oncogene. 2024; 43(7):511-523. PMC: 10857938. DOI: 10.1038/s41388-023-02918-w. View

Ishikawa A, Wada T, Nishimura S, Ito T, Okekawa A, Onogi Y . Estrogen regulates sex-specific localization of regulatory T cells in adipose tissue of obese female mice. PLoS One. 2020; 15(4):e0230885. PMC: 7117686. DOI: 10.1371/journal.pone.0230885. View

Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Morisaki T . Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. J Transl Med. 2018; 16(1):87. PMC: 5883348. DOI: 10.1186/s12967-018-1458-y. View

10.

Jeon S, Hwang K, Choi K . Effect of steroid hormones, estrogen and progesterone, on epithelial mesenchymal transition in ovarian cancer development. J Steroid Biochem Mol Biol. 2016; 158:1-8. DOI: 10.1016/j.jsbmb.2016.02.005. View

11.

Scott S, Shao X, Niknafs N, Balan A, Pereira G, Marrone K . Sex-specific differences in immunogenomic features of response to immune checkpoint blockade. Front Oncol. 2022; 12:945798. PMC: 9382103. DOI: 10.3389/fonc.2022.945798. View

12.

Kim S, Kim J . Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. ESMO Open. 2021; 6(3):100149. PMC: 8314869. DOI: 10.1016/j.esmoop.2021.100149. View

13.

Mukherjee K, Syed V, Ho S . Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene. 2005; 24(27):4388-400. DOI: 10.1038/sj.onc.1208623. View

14.

Bagbudar S, Karanlik H, Cabioglu N, Bayram A, Ibis K, Aydin E . Prognostic Implications of Immune Infiltrates in the Breast Cancer Microenvironment: The Role of Expressions of CTLA-4, PD-1, and LAG-3. Appl Immunohistochem Mol Morphol. 2021; 30(2):99-107. DOI: 10.1097/PAI.0000000000000978. View

15.

Chovatiya N, Kaur K, Huerta-Yepez S, Chen P, Neal A, DiBernardo G . Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity. Cancer Immunol Immunother. 2022; 71(12):2929-2941. PMC: 10991924. DOI: 10.1007/s00262-022-03192-7. View

16.

Potter S, Dwyer R, Curran C, Hennessy E, Harrington K, Griffin D . Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones. Breast Cancer Res Treat. 2008; 115(2):279-87. DOI: 10.1007/s10549-008-0078-2. View

17.

Mauro L, Seibel M, Diep C, Spartz A, Perez Kerkvliet C, Singhal H . Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models. J Clin Endocrinol Metab. 2021; 106(7):1929-1955. PMC: 8499172. DOI: 10.1210/clinem/dgab195. View

18.

He M, Yu W, Chang C, Miyamoto H, Liu X, Jiang K . Estrogen receptor α promotes lung cancer cell invasion via increase of and cross-talk with infiltrated macrophages through the CCL2/CCR2/MMP9 and CXCL12/CXCR4 signaling pathways. Mol Oncol. 2020; 14(8):1779-1799. PMC: 7400793. DOI: 10.1002/1878-0261.12701. View

19.

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

20.

Offner H, Vandenbark A . Congruent effects of estrogen and T-cell receptor peptide therapy on regulatory T cells in EAE and MS. Int Rev Immunol. 2005; 24(5-6):447-77. DOI: 10.1080/08830180500371462. View